Laura is the vice president of content of Managed Healthcare Executive® (MHE) and all its brands, including Formulary Watch® and Chief Healthcare Executive®. She has been working on MHE since 2019 and has been with MHE's parent company, MJH Life Sciences®, since 2011. She has an MA in business and economic reporting from New York University.
You can reach her at firstname.lastname@example.org or you can connect with her on LinkedIn or Twitter.
Differences in Patient Characteristics, Treatment of EoE by Allergists and GastroenterologistsDecember 12th 2022
Most (91%) of the patients were seen by gastroenterologists. Those seen by allergists were more likely to have comorbid atopic conditions, such as asthma, allergic rhinitis and atopic dermatitis.
Long-term Use of Dupixent Effective for Patients With Asthma Regardless of CRSwNP StatusDecember 9th 2022
Patients with severe asthma with or without coexisting chronic rhinosinusitis and nasal polyps (CRSwNP) experienced continued improvements in exacerbations and lung function in an extension study.
Variation by Age of EoE Symptoms May Contribute to Delayed Diagnosis for Some PatientsDecember 6th 2022
Patients with eosinophilic esophagitis experience a range of symptoms that can vary by age, which may contribute to younger patients experiencing a delay in diagnosis, according to a poster presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
Real-World Study Shows Dupixent Improves AD Symptoms in Children Under 12 YearsOctober 5th 2022
A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
WellDyne's David Skomo Highlights the Need to Reframe How Obesity Is ViewedSeptember 14th 2022
Payers need to reframe how they view obesity as not just a health and wellness issue, but as a progressive chronic disease that needs medication, explained David Skomo, RPh, chief operations officer at WellDyne.
Gregory Warren Discusses Measuring Value and Scaling Up Value-Based ContractingSeptember 13th 2022
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease BurdenSeptember 7th 2022
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Management of EoE May Need to Be Rethought to Reduce Treatment Burden, Impact on Quality of LifeSeptember 2nd 2022
Therapeutic goals of reducing eosinophil counts below a certain level in eosinophilic esophagitis (EoE) has a marginal benefit for the impact on quality of life and treatment burden.
FDA Expands Approval of Dupixent to Children 6 Months and Older With Moderate-to-Severe Atopic DermatitisJune 10th 2022
Dupixent was already approved for patients 6 years and older. The new approval makes the drug available to children 6 months to 5 years whose atopic dermatitis is inadequately controlled.
There Remains an Unmet Need for EoE Treatments That Provide Effective, Long-term Disease ControlMay 5th 2022
Patients with eosinophilic esophagitis (EoE) are faced with delayed diagnosis, burdens related to symptoms, quality of life and cost, but lack targeted systemic therapies to improve long-term disease control.
Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy SummitMay 4th 2022
In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.